Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer

NCT01090011 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

171

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: Cetuximab
DRUG: Cetuximab
DRUG: BIBW 2992
DRUG: BIBW 2992

Sponsor

Boehringer Ingelheim